DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Nectar Lifesciences Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·6 Oct 2026, 5:38 am

Nectar Lifesciences

Nectar Lifesciences Limited has informed stock exchanges that it has received a certificate under SEBI’s Depositories and Participants Regulations, 2018. This document confirms that the company’s shares are eligible for electronic settlement in the demat account of investors, as per regulatory standards.

For investors, this is a procedural update that ensures the stock can be traded and settled electronically without any issues. It confirms the company's compliance with market infrastructure rules, which is essential for maintaining a smooth trading environment.

Investors should note that this is a routine regulatory filing and does not indicate any new business activity or financial performance. The stock will continue to trade as usual on the exchange.